Fundraising FoxArrogene
Los Angeles, US · Delaware corporation · 1 known investors
Find your way into Arrogene
Sign up to see every warm intro you have to Arrogene
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Arrogene team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Founders & leadership
JS
JEFFREY SPERBERExecutive
MV
MAURIZIO VECCHIONEExecutive
JL
JULIA LJUBIMOVANamed on SEC filing
Board
RS
ROBERT STUCKELMANBoard director
RS
RANDOLPHE SWENSONBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$6.1M disclosed across 7 of 8 rounds · 2012–2019
▶$10KraisedOct 2019 · 1 investors · BiotechnologyRule 506(b)
▶$10KraisedOct 2019 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Larry A. CoutureExecutive Officer, Director
- James HoschDirector
- Jack KavanaughExecutive Officer, Director
- Robert SnukalDirector
- Julia LjubimovaExecutive Officer, Director
- Offering amount
- $990K
- Amount sold
- $10K
- Minimum investment
- $10K
- First sale
- Oct 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$524.9KraisedMay 2018 · 14 investors · BiotechnologyRule 506(b)
▶$524.9KraisedMay 2018 · 14 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- James HoschDirector
- Robert SnukalDirector
- Jack KavanaughExecutive Officer, Director
- Larry A. CoutureExecutive Officer, Director
- Julia LjubimovaExecutive Officer, Director
- Offering amount
- $1M
- Amount sold
- $524.9K
- Sales commissions
- $13.5K
- Placement agents
- GVC Capital LLC, Westpark Capital Inc.
- First sale
- Apr 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.7MraisedMar 2018 · 43 investors · BiotechnologyRule 506(b)
▶$2.7MraisedMar 2018 · 43 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- JULIA LJUBIMOVAExecutive Officer, Director
- Robert SnukalDirector
- Jack KavanaughExecutive Officer, Director
- James HoschDirector
- Larry A. CoutureExecutive Officer, Director
- Offering amount
- $2.8M
- Amount sold
- $2.7M
- Sales commissions
- $36.2K
- Placement agents
- GVC Capital LLC, Westpark Capital Inc.
- First sale
- Mar 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$750KraisedMar 2016 · 1 investors · BiotechnologyRule 506(b)
▶$750KraisedMar 2016 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- MAURIZIO VECCHIONEExecutive Officer, Director
- Jack KavanaughExecutive Officer, Director
- JULIA LJUBIMOVAExecutive Officer, Director
- ROBERT STUCKELMANDirector
- Randolphe SwensonDirector
- JEFFREY SPERBERExecutive Officer
- Offering amount
- $5M
- Amount sold
- $750K
- First sale
- Feb 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$250KraisedJan 2015 · 1 investors · BiotechnologyRule 506(b)
▶$250KraisedJan 2015 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- JEFFREY SPERBERExecutive Officer
- JULIA LJUBIMOVAExecutive Officer, Director
- MAURIZIO VECCHIONEExecutive Officer, Director
- ROBERT STUCKELMANDirector
- RANDOLPHE SWENSONDirector
- Offering amount
- $1M
- Amount sold
- $250K
- Minimum investment
- $25K
- Sales commissions
- $32.5K
- Placement agents
- GVC CAPITAL, WESTPARK CAPITAL
- First sale
- Dec 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$700KraisedMay 2014 · 23 investors · BiotechnologyRule 506(b)
▶$700KraisedMay 2014 · 23 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- ROBERT STUCKELMANDirector
- MAURIZIO VECCHIONEExecutive Officer, Director
- JULIA LJUBIMOVAExecutive Officer, Director
- JEFFREY SPERBERExecutive Officer
- Offering amount
- $700K
- Amount sold
- $700K
- Minimum investment
- $25K
- Sales commissions
- $91K
- Placement agents
- WESTPARK CAPITAL
- First sale
- Feb 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.1MraisedFeb 2012 · 10 investors · BiotechnologyRule 506(b)
▶$1.1MraisedFeb 2012 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- ROBERT STUCKELMANDirector
- JULIA LJUBIMOVAExecutive Officer, Director
- MAURIZIO VECCHIONEExecutive Officer, Director
- JEFFREY SPERBERExecutive Officer
- Offering amount
- $4.8M
- Amount sold
- $1.1M
- Minimum investment
- $5K
- Sales commissions
- $111.2K
- Placement agents
- WESTPARK CAPITAL
- First sale
- Jan 2012
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06
▶Undisclosed amountofferedJan 2012 · 11 investors · BiotechnologyRule 506(b)
▶Undisclosed amountofferedJan 2012 · 11 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- JEFFREY SPERBERExecutive Officer
- JULIA LJUBIMOVAExecutive Officer, Director
- MAURIZIO VECCHIONEExecutive Officer, Director
- ROBERT STUCKELMANDirector
- First sale
- Jan 2012
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- Who are Arrogene's investors?
- Arrogene's investors include Multiverse Investment.
- How much funding has Arrogene raised?
- Arrogene has disclosed $6.1M raised across 7 of its 8 known rounds.
- Where is Arrogene headquartered?
- Arrogene is headquartered in Los Angeles, US.